Aligos Therapeutics ALGS
NASDAQ ALGS
$5.14 +0.11 (+2.22%)
As of: Oct 21, 2026 · 10:21 AM EDT

Aligos Therapeutics (ALGS) Receivables (2026)

Updated

Aligos Therapeutics (ALGS) posted Receivables of $27.78 million for Q2 2026.

Analysis

Aligos Therapeutics (ALGS) Receivables (2026) Analysis & Trends

Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Receivables (Qtr)
1 Eli Lilly 1,131.65 Bn 1,100.24 Bn 19.71 Bn 23.48 Bn
2 Johnson & Johnson 615.89 Bn 534.41 Bn 17.26 Bn 19.05 Bn
3 AbbVie 505.03 Bn 478.14 Bn 12.70 Bn 13.82 Bn
4 Merck 368.78 Bn 323.16 Bn 12.21 Bn 12.56 Bn
5 Novartis Ag 298.66 Bn 262.65 Bn 11.24 Bn 9.64 Bn
6 Astrazeneca 262.09 Bn 235.78 Bn 12.86 Bn 15.68 Bn
7 Amgen 236.57 Bn 191.97 Bn 7.24 Bn 10.23 Bn
8 Gilead Sciences 191.05 Bn 165.25 Bn 6.22 Bn 5.06 Bn
9 Pfizer 170.60 Bn 117.25 Bn 10.94 Bn 12.49 Bn
10 Aligos Therapeutics 53.61 Mn -274.79 Mn - 27.78 Mn
Historic Data

Historic Data

Download Data
DateValue
Jun 30, 2026 27.78 Mn
API Access

Aligos Therapeutics Receivables API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=receivables&ticker=ALGS&period=max&api_key=YOUR_API_KEY